MG1

Minister St-Onge releases final regulations for the Online News Act

Retrieved on: 
Friday, December 15, 2023
Online, Canadian Broadcasting Corporation, Indigenous self-government in Canada, MG1, Act, Government, CAD, Internet, Advertising, CRTC, Social media, News, The Act, Regulation, Cryptocurrency, Financial adviser, Online shopping, Publishing, Distribution (marketing), Real estate

Today, the Government of Canada released the final regulations for the Online News Act.

Key Points: 
  • Today, the Government of Canada released the final regulations for the Online News Act.
  • The Canadian Radio-television and Telecommunications Commission (CRTC) is the arm's-length body that oversees the bargaining framework established by the Act.
  • Draft Regulations were published online between September 2, 2023, and October 2, 2023, for public consultation.
  • The Regulations establish the factors that determine if the Online News Act applies to a digital platform and when it is required to notify the CRTC that the Act applies to it.

New Study Identifies Potential Immunotherapy Target for Malaria

Retrieved on: 
Monday, May 9, 2022
Antibody, Society, Immune system, University, Mortality, GLOBE, MG1, Experimental biology, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), C3, Immunotherapy, Immunity, Publishing, Therapy, Disease, Experimental Biology and Medicine, Genetic variation, Risk, Vaccine, Medicine, Malaria

WASHINGTON, May 09, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine ( Volume 247, Issue 8, April, 2022 ) identifies a new target for malaria treatment.

Key Points: 
  • WASHINGTON, May 09, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine ( Volume 247, Issue 8, April, 2022 ) identifies a new target for malaria treatment.
  • African children with malaria suffer from severe malarial anemia, which is caused by both the destruction and reduced production of red blood cells.
  • While there are currently approved immunotherapies for malaria, these findings suggest that efforts aimed at targeting the complement system may offer important treatment alternatives for Malaria.
  • These important studies provide a potential target for immunotherapy against malaria."

First Nasally-Administered Pharmaceutical Treatment for Dry Eye Disease Approved by US FDA with Aptar’s Nasal Pump System

Retrieved on: 
Monday, October 25, 2021
Packaging, FDA, Health, Manufacturing, General Health, Optical, Science, Duane syndrome, Financial condition report, Engineering, Securities Act of 1933, Nasal spray, Administration, AptarGroup, Drug development, Vaccination, CNS, ATR, Analysis, U.S. Securities and Exchange Commission, Patient, Security (finance), FDA, Result, NYSE, Nose, American Journal, U.S. FDA, Homeostasis, Technology, Forward-looking statement, Food, Nasal mucosa, CEO, American Journal of Ophthalmology, Combination product, Multimedia, Regulatory affairs, Allergic rhinitis, Dry eye syndrome, Pain, Drug Quality and Security Act, Beauty, Health, Risk, CPS, Prevalence, Securities Exchange Act of 1934, MG1, Form, Pharmaceutical industry, Animal, Dry Eye Disease, Aptar, DRY EYE DISEASE, APTAR

View the full release here: https://www.businesswire.com/news/home/20211025005101/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211025005101/en/
    TYRVAYA, a highly selective cholinergic agonist, is the first nasally-administered pharmaceutical therapy to treat the signs and symptoms of dry eye disease to have been approved by the U.S. FDA.
  • This approval makes Aptars Cartridge Pump System a key component of the first and only U.S. FDA-approved pharmaceutical therapy to deliver treatment for the signs and symptoms of dry eye disease, an ophthalmic condition, via the nasal route and re-confirms Aptars expertise for developing innovative drug delivery solutions.
  • We are pleased that our proven CPS nasal system is now a multidose delivery option for patients suffering from dry eye disease.
  • Dry eye disease is a multifactorial chronic disease of the ocular surface characterized by a loss of homeostasis of the tear film, resulting in a multitude of symptoms.